Antiplatelet therapy in neuroendovascular procedures requires careful management due to variable pharmacodynamic responses to agents like clopidogrel.
How should clinicians manage antiplatelet therapy in patients undergoing neuroendovascular procedures?
This review provides clinical recommendations for managing the variable pharmacodynamic response to antiplatelet agents like clopidogrel in patients undergoing neuroendovascular procedures.
Neuroendovascular techniques for treating cerebral aneurysms and other cerebrovascular pathology are increasingly becoming the standard of care. Intraluminal stents, aneurysm coils, and other flow diversion devices typically require concomitant antiplatelet therapy to reduce thromboembolic complications. The variability inherent with the pharmacodynamic response to common antiplatelet agents such as aspirin and clopidogrel complicates optimal selection of antiplatelet agents by clinicians. This review serves to discuss the literature related to antiplatelet use in neuroendovascular procedures and provides recommendations for clinicians on how to approach patients with variable response to antiplatelet agents, particularly clopidogrel.
Kim et al. (Fri,) conducted a review in Cerebral aneurysms and other cerebrovascular pathology. Antiplatelet therapy was evaluated. Antiplatelet therapy in neuroendovascular procedures requires careful management due to variable pharmacodynamic responses to agents like clopidogrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: